BURZYNSKI RESEARCH INSTITUTE INC

BZYR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $0 $0 $0 $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $1.0M $865.0K $718.5K $759.5K $1.0M $1.2M $1.1M $1.3M
SG&A Expense $340.3K $470.4K $197.8K $217.1K $278.8K $431.8K $491.8K $332.6K
Operating Income $-1.4M $-1.3M $-916.3K $-976.7K $-1.3M $-1.6M $-1.6M $-1.6M
Operating Margin
Interest Expense
Pretax Income $-1.4M $-1.3M $-916.3K $-976.7K $-1.2M $-1.6M $-1.6M $-1.6M
Income Tax Expense $0 $0 $0 $0 $0 $0
Net Income $-1.4M $-1.3M $-916.3K $-976.7K $-1.2M $-1.6M $-1.6M $-1.6M
Net Margin
EPS (Basic) $-0.01 $-0.01 $-0.01 $-0.01 $-0.01 $-0.01 $-0.01 $-0.01
EPS (Diluted) $-0.01 $-0.01 $-0.01 $-0.01 $-0.01 $-0.01 $-0.01 $-0.01
Shares Outstanding (Basic) 131.4M 131.4M 131.4M 131.4M 131.4M 131.4M 131.4M 131.4M
Shares Outstanding (Diluted) 131.4M 131.4M 131.4M 131.4M 131.4M 131.4M 131.4M 131.4M
Dividends Per Share
← Newer Page 1 of 2 Older →